Session III: Obstacles and Opportunities for Optimal Preparedness

Moderator: Gary Roselle, MD, Program Director for Infectious Diseases, Department of Veterans Affairs Central Office

1:00–1:20

Partnering with the Private Medical System

Gordon Grundy, MD, Regional Medical Director, Aetna Inc.

1:20–1:35

Discussion

1:35–1:55

Vaccine Development and Production Issues

Philip Hosbach, Vice President of New Products and Immunization Policy, Aventis Pasteur SA

1:55–2:10

Discussion

2:10–2:30

Ensuring an Adequate Stockpile of Antivirals

Paul Brown, PhD, Global Task Force Leader for Tamiflu™ Pandemic Planning, F. Hoffmann La-Roche, Switzerland

2:30–2:45

Discussion

2:45–3:05

Chasing the Elusive Virus: Preparing for the Future by Examining the Past

Jeffery K. Taubenberger, MD, PhD, Chair, Department of Molecular Pathology, Armed Forces Institute of Pathology, U.S. Department of Defense

3:05–3:20

Discussion

3:20

Break

Session IV: Panel Discussion—Innovating Past Barriers

Moderator: Joshua Lederberg, PhD, Nobel Laureate, Sackler Foundation Scholar, Rockefeller University

3:30–3:45

Strategies for Control of Influenza by Targeting Broadly Conserved Viral Features

Suzanne Epstein, PhD, Center for Biologics Evaluation and Research, Food and Drug Administration

3:45–4:10

Mathematical Modeling: Containing Pandemic Influenza with Vaccines and Antivirals

Ira Longini, MD, Rollins School of Public Health, Emory University, Atlanta, GA

March Lipsitch, PhD, Harvard School of Public Health, Boston, MA



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement